Skip to content

Meat 3.0 — How Cultured Meat is Making its Way to the Market

Karin Verzijden, Jasmin Buijs

Developments in the field of cultured meat go fast. At the end of 2019 and at the beginning of 2020, several companies on both sides of the Atlantic announced new funding rounds. Furthermore, an alternative for the controversial fetal bovine serum (FBS), a by-product made from the blood of cow fetuses, was reported to be within reach. In the Dutch Parliament, it was discussed if and how the development of cultured meat should be supported. All of these developments result in market access for cultured meat becoming more and more a reality. This article therefore aims to further clarify such market access in regulatory terms and to respond, where appropriate, to an article on this topic previously published in EFFL. Market access requirements include that the applicant makes a proposal for the name of the product. In this article, we shall therefore discuss the key question if cultured meat can actually be called ‘meat’. This article will also provide a comparison of the regulatory requirements between the EU and the US, as far as currently known. Finally, it will discuss the new EFSA transparency requirements as of 2021, which are expected to be of high impact for cultured meat companies.

Karin Verzijden, LLM, MA, and Jasmin Buijs, LLM, Msc, are lawyers at Axon Lawyers, the Netherlands, and specialized in food, feed and pharma law.


Lx-Number Search

(e.g. A | 000123 | 01)

Export Citation